Ourania Tatsis files to sell 466 common shares

Ourania Tatsis has filed a Form 144 to sell 466 shares of common stock.

Rhea-AI Filing Summary

Ourania Tatsis has filed a Form 144 to sell 466 shares of common stock. The shares were acquired through restricted stock vesting on 02/10/2026 as compensation and are planned to be sold around 02/11/2026 through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $214,560.38.

In the prior three months, Tatsis sold 4,500 common shares on 12/03/2025 for gross proceeds of $2,024,955.40 and another 4,500 shares on 01/07/2026 for $2,137,455.00.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the VRTX Form 144 filing for Ourania Tatsis disclose?

The filing discloses that Ourania Tatsis plans to sell 466 common shares under Rule 144. It provides details on how the shares were acquired, planned sale timing, market value, broker, and recent historical share sales over the last three months.

How many VRTX shares is Ourania Tatsis planning to sell under this Form 144?

The notice states that 466 shares of common stock are planned for sale. These shares are to be sold through Fidelity Brokerage Services LLC on NASDAQ, with an approximate sale date of 02/11/2026 and an aggregate market value listed as $214,560.38.

How did Ourania Tatsis acquire the 466 VRTX shares to be sold?

The 466 common shares were acquired on 02/10/2026 through restricted stock vesting. The filing identifies the issuer as the source of the shares and classifies the nature of payment as compensation, meaning the shares were awarded rather than bought for cash.

What is the aggregate market value of the VRTX shares in this planned sale?

The Form 144 lists an aggregate market value of $214,560.38 for the 466 common shares to be sold. This value reflects the market price used in the filing and helps indicate the dollar size of the planned transaction at the time of the notice.

Which broker and exchange are involved in the VRTX Form 144 sale by Ourania Tatsis?

The filing shows Fidelity Brokerage Services LLC as the broker handling the trade. The common shares are planned to be sold on NASDAQ, with the approximate date of sale given as 02/11/2026 in the securities information section.

What VRTX share sales has Ourania Tatsis made in the past three months?

The document reports that 4,500 common shares were sold on 12/03/2025 for gross proceeds of $2,024,955.40, and another 4,500 shares on 01/07/2026 for $2,137,455.00, showing recent sizable insider sales before this new planned transaction.

How many VRTX shares are outstanding as referenced in this Form 144?

The securities information section lists 253,718,831 shares outstanding of the issuer’s common stock. This figure provides context for the company’s total equity base relative to the 466-share sale planned by Ourania Tatsis in this notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/11/2026 - 09:47 AM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001789815
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	VERTEX PHARMACEUTICALS INC / MA
SEC File Number	000-19319
Address of Issuer	50 NORTHERN AVENUE BOSTON MASSACHUSETTS 02210
Phone	6173416393
Name of Person for Whose Account the Securities are To Be Sold	Tatsis Ourania
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	466	214560.38	253718831	02/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	02/10/2026	Restricted Stock Vesting	Issuer			466	02/10/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ourania Tatsis 50 Northern Avenue Boston MA 02210	Common	12/03/2025	4500	2024955.40
Ourania Tatsis 50 Northern Avenue Boston MA 02210	Common	01/07/2026	4500	2137455.00

144: Remarks and Signature

Remarks
Date of Notice	02/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/21/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Eric Janiak, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Ourania Tatsis
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)